Skip to main content

Table 2 Inclusion and exclusion criteria for longitudinal seroconversion follow-up (to include baseline serostatus survey)

From: A cluster-randomized, placebo-controlled trial to evaluate the efficacy of a spatial repellent (Mosquito Shield™) against Aedes-borne virus infection among children ≥ 4–16 years of age in the Gampaha District, Sri Lanka: study protocol (the AEGIS program)

Longitudinal seroconversion follow-up (to include baseline serostatus survey) Individual level

Inclusion criteria

Exclusion criteria

≥4 – 16 years of age

Plans to stay in residence and/or study area for a minimum of 24 months

Resident of household or frequent visitor (~20% of day hours in house/months)

<4 and >16 years of age

Plans to leave residence and/or study area within next 24 months

Temporary visitor to household (<20% of day hours in house/months)